Leerink Partnrs Has Pessimistic View of IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.21) for the quarter, down from their previous forecast of ($1.18). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.60) EPS, FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($1.31) EPS.

IONS has been the subject of several other reports. Redburn Atlantic initiated coverage on Ionis Pharmaceuticals in a report on Monday, March 31st. They issued a “neutral” rating and a $39.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. StockNews.com raised Ionis Pharmaceuticals to a “sell” rating in a research report on Tuesday, March 18th. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday. Finally, HC Wainwright initiated coverage on shares of Ionis Pharmaceuticals in a research note on Monday, April 7th. They set a “buy” rating and a $45.00 price objective for the company. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.72.

Ionis Pharmaceuticals Stock Up 0.2 %

Ionis Pharmaceuticals stock opened at $28.40 on Friday. The stock has a market cap of $4.51 billion, a PE ratio of -9.34 and a beta of 0.29. The stock has a fifty day moving average of $30.93 and a 200 day moving average of $34.31. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals has a one year low of $23.95 and a one year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. During the same period last year, the company earned $0.12 EPS. Ionis Pharmaceuticals’s revenue for the quarter was down 30.2% on a year-over-year basis.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Signaturefd LLC grew its stake in Ionis Pharmaceuticals by 160.0% during the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock worth $33,000 after buying an additional 584 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Ionis Pharmaceuticals by 193.5% in the fourth quarter. Huntington National Bank now owns 951 shares of the company’s stock valued at $33,000 after acquiring an additional 627 shares during the period. Lindbrook Capital LLC grew its position in shares of Ionis Pharmaceuticals by 183.8% during the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock worth $36,000 after acquiring an additional 671 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in Ionis Pharmaceuticals in the 4th quarter valued at $62,000. Finally, Venturi Wealth Management LLC acquired a new stake in Ionis Pharmaceuticals during the 4th quarter worth $107,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Patrick R. O’neil sold 6,165 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total transaction of $194,937.30. Following the completion of the sale, the executive vice president now owns 57,452 shares in the company, valued at $1,816,632.24. The trade was a 9.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eric Swayze sold 1,367 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $32.31, for a total transaction of $44,167.77. Following the sale, the executive vice president now owns 48,017 shares of the company’s stock, valued at $1,551,429.27. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,167 shares of company stock valued at $2,010,458. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.